Long-acting injectable HIV prevention for breastfeeding new mothers
Linking HIV Prevention and post-partum care: Safety, efficacy and feasibility of cabotegravir-LA PrEP in high-risk breastfeeding population in Botswana
['FUNDING_R01'] · BETH ISRAEL DEACONESS MEDICAL CENTER · NIH-10907762
This project looks at whether a long-acting injectable HIV prevention shot (cabotegravir) given after childbirth can safely protect breastfeeding women at high risk of HIV.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BETH ISRAEL DEACONESS MEDICAL CENTER (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-10907762 on ClinicalTrials.gov |
What this research studies
You would be offered a long-acting injectable called cabotegravir (CAB-LA) soon after giving birth and invited to return for follow-up visits that are provided alongside your baby's care. The team will track your health and your baby's health while you breastfeed to watch for side effects and any HIV infections. The work focuses on high-risk postpartum women in Botswana and tests whether starting CAB-LA in the hospital and linking follow-up with pediatric visits makes prevention easier to access. The study combines clinical visits, safety monitoring, and ongoing follow-up to learn if this approach is feasible and safe for breastfeeding mothers.
Who could benefit from this research
Good fit: Ideal candidates are postpartum breastfeeding women in the study area of Botswana who are at increased risk of acquiring HIV and can attend local follow-up visits.
Not a fit: Women who are not breastfeeding, not at elevated HIV risk, or unable to attend the study clinics are unlikely to benefit from this specific program.
Why it matters
Potential benefit: If successful, this approach could reduce HIV infections in postpartum breastfeeding women and help prevent HIV in their infants.
How similar studies have performed: Large trials have shown cabotegravir injections prevent HIV better than daily oral PrEP in women, but data on safety during breastfeeding remain limited.
Where this research is happening
BOSTON, UNITED STATES
- BETH ISRAEL DEACONESS MEDICAL CENTER — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZASH, REBECCA MARIE — BETH ISRAEL DEACONESS MEDICAL CENTER
- Study coordinator: ZASH, REBECCA MARIE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus